Melatonin improves the therapeutic role of mesenchymal stem cells in diabetic rats
El-Dakdoky, M.H.; Haggag, N.Z.; Rashed, L.A.; Hassen, M.T.; Kadry, shadia;
Abstract
The present study aimed to investigate the role of bone marrow mesenchymal stem cells (MSCs)
and/or melatonin (MT) for improvement of b-cell functions in STZ diabetic rats. Male albino rats
(130–150 g) were divided into six groups. Control group: received phosphate-buffered saline (PBS);
melatonin group received melatonin (10 mg/kg b.wt./day for 2 months by oral gavage); diabetic
untreated group; diabetic group treated with melatonin; diabetic group treated with MSCs (a single
intravenous injection of 3 106 cell in PBS); and diabetic group co-treated with stem cells and melatonin.
The results showed significant improvement in glucose, insulin, total antioxidant, and malondialdehyde
level in diabetic rats treated with either MSCs alone or in combination with melatonin. The
imumuno-histochemical analysis showed that MSCs and/or melatonin treatment reduced the rate of
inflammation and apoptosis of the islet cells as well as increased the rate of pancreatic cell division.
Such results were indicated by a significant improvement in the level of TNF-a, IL-10, PCNA, and caspase-3
to levels very close to the control. Co-treatment of MSCs and MT resulted in an improvement in
the tissue of the pancreas and reduced number of damaged b-cells. It can be concluded that co-treatment
of stem cells and melatonin has a significant role in restoring the structural and functional efficiency
of b-cells in the pancreas more than stem cells alone. Such results may be due to the role of
melatonin as an antioxidant in increasing the efficiency and vitality of stem cells.
and/or melatonin (MT) for improvement of b-cell functions in STZ diabetic rats. Male albino rats
(130–150 g) were divided into six groups. Control group: received phosphate-buffered saline (PBS);
melatonin group received melatonin (10 mg/kg b.wt./day for 2 months by oral gavage); diabetic
untreated group; diabetic group treated with melatonin; diabetic group treated with MSCs (a single
intravenous injection of 3 106 cell in PBS); and diabetic group co-treated with stem cells and melatonin.
The results showed significant improvement in glucose, insulin, total antioxidant, and malondialdehyde
level in diabetic rats treated with either MSCs alone or in combination with melatonin. The
imumuno-histochemical analysis showed that MSCs and/or melatonin treatment reduced the rate of
inflammation and apoptosis of the islet cells as well as increased the rate of pancreatic cell division.
Such results were indicated by a significant improvement in the level of TNF-a, IL-10, PCNA, and caspase-3
to levels very close to the control. Co-treatment of MSCs and MT resulted in an improvement in
the tissue of the pancreas and reduced number of damaged b-cells. It can be concluded that co-treatment
of stem cells and melatonin has a significant role in restoring the structural and functional efficiency
of b-cells in the pancreas more than stem cells alone. Such results may be due to the role of
melatonin as an antioxidant in increasing the efficiency and vitality of stem cells.
Other data
| Title | Melatonin improves the therapeutic role of mesenchymal stem cells in diabetic rats | Authors | El-Dakdoky, M.H. ; Haggag, N.Z. ; Rashed, L.A. ; Hassen, M.T. ; Kadry, shadia | Keywords | Mesenchymal stem cells; melatonin; diabetes; male albino rats | Issue Date | 2018 | Publisher | Informa UK Limited Taylor & Francis | Source | 0 | Journal | Toxicology Mechanisms and Methods | DOI | 1-10 http://www.scopus.com/inward/record.url?eid=2-s2.0-85047319785&partnerID=MN8TOARS 1537-6524 10.1080/15376516.2018.1471634 |
PubMed ID | 29716418 | Scopus ID | 2-s2.0-85047319785 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.